Simon Rule

机构：AstraZeneca (United Kingdom), University of Liverpool, AstraZeneca (Spain) · ORCID：0000-0001-8937-6351

发表论文 334 篇 · 总被引 11905 次 · h-index 52

代表论文

• Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (2023 · Leukemia · 被引 65)
• Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib (2024 · Blood · 被引 47)
• Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors (2023 · Haematologica · 被引 19)
• Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial (2024 · The Lancet Haematology · 被引 14)
• Characterization of Mechanisms of Resistance in Previously Treated Chronic Lymphocytic Leukemia (CLL) From a Head‐to‐Head Trial of Acalabrutinib Versus Ibrutinib (2023 · Hematological Oncology · 被引 12)
• Extended Follow-up and Resistance Mutations in CLL Patients Treated with Acalabrutinib (2023 · Blood · 被引 8)